CELSENTRI(TM) (maraviroc) Tablets First in a New Class of Oral HIV
Medicines in More than a Decade
TORONTO, Oct. 12 /CNW/ - The following B-Roll is available at the listed
times and co-ordinates:
DATE OF FEEDS: Monday, October 15, 2007
TIME OF FEEDS: 10:00 - 10:30 am ET
2:00 - 2:30 pm ET
CO-ORDINATES: Anik F2 C
Audio subcarrier 6.2 and 6.8
Downlink frequency 3980 vertical
TOC CFA TX 1
On-Demand Coordinates / URL available from 10:00 a.m. ET onwards, Monday,
October 15th 2007
CNW Broadcast On-Demand provides free, secure and easy-to-use broadcast
quality material direct from our website to accredited journalists worldwide.
Please contact email@example.com if you do not already have log-in rights.
STORY SUMMARY: CELSENTRI is the first in a new class of oral HIV medicine
in more than 10 years. CELSENTRI works differently than other HIV treatments;
it blocks entry of HIV into white blood cells, reducing the level of HIV in
the system of people with HIV.
CELSENTRI is the first in a class of drugs known as CCR5 antagonists,
which block a co-receptor which is the virus' main entry route into the body's
immune cells or CD4+ cells. CELSENTRI stops the R5 virus on the outside
surface of the cell before it enters, rather than fighting the virus inside
the cell as do all other classes of oral HIV medicines.
The development of CELSENTRI goes back to 1996 when a group of people
were found to have a gene mutation that left them immune to HIV. The virus was
not able to enter their immune cells. Pfizer scientists discovered the
compound which was to become CELSENTRI.
The B-roll will feature:
Dr. Sharon Walmsley, MSc, MD, FRCPC Department of Medicine, University of
Dr. Cécile Tremblay, FRCPC Directrice UHRESS du CHUM, microbiologiste
Dr. Manos Perros, Executive Director, Head of Antiviral Research, Pfizer
Global Research and Development
STATIONS, FOR FURTHER INFORMATION, PLEASE CALL: Teresa Pavlin,
Fleishman-Hillard, at 416-645-3641 or Julie-Catherine Racine, Pfizer Canada,
at 514-693-4602. For technical information DURING the feed, please call
As with all CNW Broadcast feeds, this release is offered for your free
and unrestricted news use. Comments regarding the content and quality are
For further information:
For further information: CNW BROADCAST, TORONTO (416) 863-5615